Back to Journals » Clinical Epidemiology » Volume 5 » Supplement 1 Comorbidity and Cancer Survival

Comorbidity and survival of Danish lung cancer patients from 2000–2011: a population-based cohort study

Authors Deleuran T, Thomsen RW, Nørgaard M, Jacobsen JB, Rasmussen TR, Søgaard M

Received 1 May 2013

Accepted for publication 10 June 2013

Published 1 November 2013 Volume 2013:5(Supplement 1 Comorbidity and Cancer Survival) Pages 31—38

DOI https://doi.org/10.2147/CLEP.S47473

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4


Thomas Deleuran,1,2 Reimar Wernich Thomsen,1 Mette Nørgaard,1 Jacob Bonde Jacobsen,1 Torben Riis Rasmussen,3 Mette Søgaard1

1Department of Clinical Epidemiology, 2Department of Medicine V, Hepatology and Gastroenterology, 3Department of Respiratory Medicine, Aarhus University Hospital, Aarhus, Denmark

Objective: To examine lung cancer survival and the impact of comorbidity in the Central Denmark Region from 2000 to 2011.
Methods: We performed a population-based cohort study of lung cancer patients diagnosed during four 3-year calendar periods (2000–2002, 2003–2005, 2006–2008, and 2009–2011) in the Central Denmark Region. The Danish National Registry of Patients was used to identify 9,369 incident lung cancer patients, and to obtain data on their Charlson comorbidity index score, categorized as no (score = 0), medium (score = 1–2), or high (score ≥3) level comorbidity. We calculated 1- and 5-year survival in different calendar time periods overall, and by age, sex, and level of comorbidity, and used Cox regression to compute mortality rate ratios (MRR) for each level of comorbidity versus no comorbidity in different calendar time periods.
Results: Overall 1-year survival increased from 31% in 2000–2002 to 37% in 2009–2011, while the 5-year survival increased from 10% in 2000–2002 to predicted 13% in 2009–2011 with the largest improvement observed for women and patients less than 80 years. The adjusted 1-year MRR in patients with high comorbidity compared with those without comorbidity was 1.23 (95% confidence interval [CI]: 1.05–1.46) in 2000–2002 and 1.35 (95% CI: 1.17–1.56) in 2009–2011. The corresponding adjusted 5-year MRRs were 1.21 (95% CI: 1.04–1.40) in 2000–2002 and 1.26 (95% CI: 1.11–1.42) in 2009–2011.
Conclusion: Lung cancer patients' survival increased from 2000 to 2011 in the Central Denmark Region, most prominently for women under 80 years and patients with no, or medium level of comorbidity. Their prognosis remained nonetheless dismal with overall 5-year survival of 13%, and comorbidity remained a negative prognostic factor.

Keywords: mortality, lung cancer, comorbidity, time-trends

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]